Cooley Shortlisted for Seven Awards at ALB China Law Awards 2026

Why It Matters

The nominations validate Cooley’s growing foothold in China’s high‑tech and life‑sciences sectors and enhance its cross‑border advisory reputation, positioning the firm ahead of rivals in a competitive legal market.

Key Takeaways

• Seven ALB China Law Awards nominations across deal categories.
• Recognized for major IPOs: HK$781 M Butong, HK$14.28 B Seres.
• International Law Firm of the Year nomination boosts global profile.
• Partner Yiming Liu shortlisted for International Dealmaker of the Year.
• Showcases Cooley’s strength in China tech and life‑sciences.

Pulse Analysis

The Asian Legal Business China Law Awards have become a benchmark for legal excellence in the region, and Cooley’s seven nominations signal a strong endorsement from peers and clients alike. By securing nods in both firm‑wide and deal‑specific categories, Cooley demonstrates its ability to compete with entrenched local firms while maintaining a global perspective. The International Law Firm of the Year and International Deal Firm of the Year shortlists, in particular, highlight the firm’s cross‑border expertise, a critical asset as Chinese companies increasingly seek foreign capital and strategic partnerships.

Cooley’s deal recognitions stem from two marquee IPOs that showcase its capital‑markets prowess. Representing Butong Group in a HK$781 million offering and advising underwriters on Seres Group’s HK$14.28 billion listing underscore the firm’s depth in equity financing and its capacity to navigate complex regulatory environments. These transactions also reflect the broader surge in Chinese tech and life‑sciences listings, where sophisticated legal counsel can differentiate successful market entries. Cooley’s involvement signals confidence from issuers and investors in the firm’s transactional rigor and industry knowledge.

Beyond individual deals, the shortlist reinforces Cooley’s strategic emphasis on China’s innovation ecosystem. With offices in Beijing, Hong Kong and Shanghai, the firm is positioned to serve high‑growth tech and biotech firms from formation through exit, leveraging its global network to facilitate inbound and outbound deals. As competition intensifies among international firms for market share, the ALB nominations provide Cooley with a marketing lever to attract new clients and deepen existing relationships, potentially translating into a stronger pipeline of cross‑border transactions in the coming years.